



Substitute for form 1449aP TO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****Complete if Known**

Sheet	1	of	1	Application Number	10/049,427
				Filing Date	May 6, 2002
				First Named Inventor	Thor
				Art Unit	1617
				Examiner Name	Mitchell
				Attorney Docket Number	4220-78-PUS

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
		PCT	-					
			-					
			-					

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner Initials*	Cite No. ¹	
		McMahon, C., J. Sex Med., Supp2:94-5 (2005)
		Day, SJ and Altman, DG Blinding in Clinical Trials and Other Studies, <i>British Medical Journal</i> , 321:504 (2000)
		Swartz, D.A. (1994), Sertraline hydrochloride for premature ejaculation. J Urol 151 (Suppl.); 345A

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.